The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
The role of stromal cells and the tumour microenvironment in general in modulating tumour sensitivity is increasingly becoming a key consideration for the development of active anticancer therapeutics. Here, we discuss how these tumour-stromal interactions affect tumour cell signalling, survival, proliferation and drug sensitivity. Particular emphasis is placed on the ability of stromal cells to confer - to tumour cells - resistance or sensitization to different classes of therapeutics, depending on the specific microenvironmental context. The mechanistic understanding of these microenvironmental interactions can influence the evaluation and selection of candidate agents for various cancers, in both the primary site as well as the metastatic setting. Progress in in vitro screening platforms as well as orthotopic and 'orthometastatic' xenograft mouse models has enabled comprehensive characterization of the impact of the tumour microenvironment on therapeutic efficacy. These recent advances can hopefully bridge the gap between preclinical studies and clinical trials of anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that the activated stroma is a disease-de fi ning factor, highlighting it as an important player in cancer cell invasion/extravasation, migration, angiogenesis, drug resistance [6,7], cancer stem cell maintenance [8], and immunosurveillance evasion [6,9,10].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [6]
In the citing paper
“There is increasing evidence that the activated stroma is a disease-de fi ning factor, highlighting it as an important player in cancer cell invasion/extravasation, migration, angiogenesis, drug resistance [6,7], cancer stem cell maintenance [8], and immunosurveillance evasion [6,9,10].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [6]
In the citing paper
“Hence, tumor-stromal interactions, the composition of the TME and tumor immune status all contribute to determining tumor growth, metastasis, angiogenesis and therapy resistance (McMillin et al., 2013; Fontana et al., 2021; Rodrigues et al., 2021; Xiao and Yu, 2021), thereby critically influencing the clinical outcome of cancer patients.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as McMillin et al., 2013
In the citing paper
“In addition, many studies have highlighted the critical importance of the microenvironment for promoting or suppressing tumor growth, invasion, metastasis, and response to therapy (McMillin et al., 2013; Fontana et al., 2021; Rodrigues et al., 2021; Xiao and Yu, 2021).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as McMillin et al., 2013
In the citing paper
“The non‐malignant cells and matrixcomponents which make up the TME have been shown to playa role in tumor cell survival, proliferation,andtreatment resistance (48).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [48]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,247
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Cited by
Items 201–300 of 491
Flood, M. P., Narasimhan, V., Wilson, K., Lim, W. M., Ramsay, R. G., Michael, M., & Heriot, A. G. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10829-x · Cited by 36
The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma
Burwick, N. R., Zhang, M. Y., de la Puente, P., Azab, A. K., Hyun, T. S., Ruiz‐Gutierrez, M., Sánchez-Bonilla, M., Nakamura, T., Delrow, J. J., MacKay, V. L., et al. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.01.007 · Cited by 32
Awareness of intratumoral bacteria and their potential application in cancer treatment
Liang, Y., Li, Q., Liu, Y., Guo, Y., & Li, Q. (2023) · Discover Oncology · doi:10.1007/s12672-023-00670-x · Cited by 33
“This finding suggests that microbial metabolites in the TME may be a potential source of lipid metabolism in cancer cells to promote cancer cell proliferation and invasion [64].”
BackgroundInfluentialBorges, R., Pelosine, A. M., de Souza, A. C. S., Machado, J., Justo, G. Z., Gamarra, L. F., & Marchi, J. (2022) · Materials · doi:10.3390/ma15249082 · Cited by 32
Development of TRACER: tissue roll for analysis of cellular environment and response
Rodenhizer, D., Cojocari, D., Wouters, B. G., & McGuigan, A. P. (2016) · Biofabrication · doi:10.1088/1758-5090/8/4/045008 · Cited by 36
Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma
Santoro, M., Menegaz, B. A., Lamhamedi-Cherradi, S.-E., Molina, E. R., Wu, D., Priebe, W., Ludwig, J. A., & Mikos, A. G. (2016) · Tissue Engineering Part A · doi:10.1089/ten.tea.2016.0369 · Cited by 32
“3,10,11 These observations, and many others, demonstrate that non-malignant elements of the tumor microenvironment play a central role in disease progression, and, therefore, may be considered additional targets for therapeutic interventions.”
InfluentialTurner, T. H., Alzubi, M. A., Sohal, S. S., Olex, A. L., Dozmorov, M. G., & Harrell, J. C. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4748-4 · Cited by 33
The Role of Tumor Microenvironment in Melanoma Therapy Resistance
Somasundaram, R., Herlyn, M., & Wagner, S. N. (2016) · Melanoma Management · doi:10.2217/mmt.15.37 · Cited by 32
Regan, D. P., Garcia, K. D., & Thamm, D. H. (2018) · ILAR Journal · doi:10.1093/ilar/ily019 · Cited by 31
Peela, N., Barrientos, E. S., Truong, D., Mouneimne, G., & Nikkhah, M. (2017) · Integrative Biology · doi:10.1039/c7ib00180k · Cited by 29
Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions
Thakur, A., Rana, M., Mishra, A., Kaur, C., Pan, C., & Nepali, K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116472 · Cited by 30
Chen, Q., Wang, Q., Wang, Y., Chu, Y., Luo, Y., You, H., Su, B., Li, C., Guo, Q., Sun, T., et al. (2022) · Small · doi:10.1002/smll.202107712 · Cited by 30
Abdolahinia, E. D., & Han, X. (2023) · Cancers · doi:10.3390/cancers15174266 · Cited by 30
Huang, R., Wu, D., Yuan, Y., Li, X., Holm, R., Trope, C. G., Nesland, J. M., & Suo, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112209 · Cited by 29
“The stromal cells interact with each other in a complex net by secreting distinct, abnormal molecules into ECM and contribute to tumor growth and invasiveness [3,4,5,6,7].”
BackgroundInteractions between the tumor and the blood systemic response of breast cancer patients
Dumeaux, V., Fjukstad, B., Fjøsne, H. E., Frantzen, J. O., Holmen, M. M., Rodegerdts, E., Schlichting, E., Børresen‐Dale, A., Bongo, L. A., Lund, E., et al. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005680 · Cited by 31
3D bioprinting tumor models mimic the tumor microenvironment for drug screening
Mi, X., Su, Z. Y., Yue, X., Ya, R., Yang, X. F., Qiang, L., Kong, W., Ma, Z., Zhang, C., & Wang, J. (2023) · Biomaterials Science · doi:10.1039/d3bm00159h · Cited by 29
Kroesen, M., Brok, I. C., Reijnen, D., Hout-Kuijer, M. A. V., Zeelenberg, I. S., den Brok, M. H., Hoogerbrugge, P. M., & Adema, G. J. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1663-y · Cited by 28
Bani, M. R., Decio, A., Giavazzi, R., & Ghilardi, C. (2017) · Angiogenesis · doi:10.1007/s10456-017-9549-6 · Cited by 32
Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication
Han, Y., Zhu, B., & Meng, S. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101611 · Cited by 42
“…drug resistance is influenced by factors such as the tumor microenvironment, endothelial heterogeneity, 45,198 autophagy in tumor cells, 199 stromal cell infiltration, 200 tumor types, 201 and other variables, all of which collectively impact patient response and tolerance to anti-angiogenic therapy.”
Therapeutic response differences between 2D and 3D tumor models of magnetic hyperthermia
Gupta, R., & Sharma, D. (2021) · Nanoscale Advances · doi:10.1039/d1na00224d · Cited by 28
Guo, Y., Liu, Y., Zhang, W., Luo, H., Shu, P., Chen, G., & Li, Y. (2022) · Discover Oncology · doi:10.1007/s12672-022-00466-5 · Cited by 28
“The TME characteristics plays a critical role in the responsiveness of immunotherapy [40].”
BackgroundSheng, S., Bernardo, M. M., Dzinic, S. H., Chen, K., Heath, E. I., & Sakr, W. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9767-4 · Cited by 29
Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy
Anfossi, S., & Călin, G. A. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.04 · Cited by 35
“Other mechanisms are included in the complex network of signaling the TME([118]).”
BackgroundInfluentialCNBP controls tumor cell biology by regulating tumor‐promoting gene expression
Lee, E., Lee, T. A., Yoo, H. J., Lee, S., & Park, B. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23030 · Cited by 27
Shee, K., Jiang, A., Varn, F. S., Liu, S., Traphagen, N. A., Owens, P., Ma, C. X., Hoog, J., Cheng, C., Golub, T. R., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201801241r · Cited by 28
“One relatively uncharacterized contribution of the TME is its potential ability to enhancedrug sensitivity in cancer,which has been described as “TME-induced synthetic lethality” (18).”
BackgroundEngineering the early bone metastatic niche through human vascularized immuno bone minitissues
Colombo, M. V., Bersini, S., Arrigoni, C., Gilardi, M., Sansoni, V., Ragni, E., Candiani, G., Lombardi, G., & Moretti, M. (2021) · Biofabrication · doi:10.1088/1758-5090/abefea · Cited by 26
Complex Tumor Spheroids, a Tissue-Mimicking Tumor Model, for Drug Discovery and Precision Medicine
Kaur, G., Evans, D. M., Teicher, B. A., & Coussens, N. P. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211038362 · Cited by 25
Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity
Bernardo, M. M., Kaplun, A., Dzinic, S. H., Li, X., Irish, J. C., Mujagic, A., Jakupovic, B., Back, J. B., Buren, E. C. V., Han, X., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0234 · Cited by 25
“A major impediment to permanently haltering tumor progression in the clinic is the intrinsic or acquired resistance to currently available therapies (7, 8, 12).”
BackgroundPin, E., Stratton, S. P., Belluco, C., Liotta, L. A., Nagle, R. B., Hodge, K. A., Deng, J., Dong, T., Baldelli, E., Petricoin, E. F., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.007 · Cited by 25
p110α Inhibition Overcomes Stromal Cell–Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
Guan, J., Huang, D., Yakimchuk, K., & Okret, S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0784 · Cited by 26
“Tumor resistance to cancer drugs have to a large extend been attributed to the TME, thereby contributing to MRD and relapse (26).”
BackgroundOptimization Of Cancer Treatment Through Overcoming Drug Resistance
Elshimali, Y., Wu, Y., Khaddour, H., Wu, Y., Grădinaru, D., Sukhija, H., CHUNG, S. S., & Vadgama, J. V. (2018) · Journal of Cancer Research and Oncobiology · doi:10.31021/jcro.20181107 · Cited by 25
Induced pluripotent stem cells: A new strategy to model human cancer
Bindhya, S., Sidhanth, C., Shabna, A., Krishnapriya, S., Garg, M., & Ganesan, T. S. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.12.008 · Cited by 25
Okazaki, S., Stintzing, S., Sunakawa, Y., Cao, S., Zhang, W., Yang, D., Ning, Y., Matsusaka, S., Berger, M. D., Miyamoto, Y., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30810 · Cited by 24
Khafaga, A. F., Mousa, S. A., Aleya, L., & Abdel‐Daim, M. M. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02662-3 · Cited by 27
Mas, C., Boda, B., Caul-Futy, M., Huang, S., Wiszniewski, L., & Constant, S. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.01.012 · Cited by 27
Li, W., Liu, Y., Yang, W., Han, X., Li, S., Liu, H., Gerweck, L. E., Fukumura, D., Loeffler, J. S., Yang, B. B., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2646-y · Cited by 26
Morton, J. J., Keysar, S. B., Perrenoud, L., Chimed, T.-S., Reisinger, J., Jackson, B. C., Le, P. N., Nieto, C., Gomez, K. E., Miller, B., et al. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22887 · Cited by 24
“Although traditional mouse xenograft models can partially meet this need, they cannot recapitulate interactions between cancer and immune cells within the TME.(21,22) Over the past decade, humanized mouse xenograft models have been developed to address this challenge.”
InfluentialPaindelli, C., Navone, N. M., Logothetis, C. J., Friedl, P., & Dondossola, E. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.01.027 · Cited by 24
The Role of Exosomes in Cancer Progression and Therapy
Sergazy, S., Seydahmetova, R., Gulyayev, A., Shulgau, Z., & Aljofan, M. (2025) · Biology · doi:10.3390/biology14010027 · Cited by 28
“The crosstalk presented by cellular signaling and communication networks in the tumor environment plays important roles in cancer development, progression as well as treatment [17–19].”
Lu, Z., Miao, X., Zhang, C., Sun, B., Skardal, A., Atala, A., Ai, S., Gong, J., Hao, Y., Zhao, J., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.12.005 · Cited by 38
“…the physical structure, maintains the biochemical homeostasis of the tumor microenvironment [20], and regulates most tumor cell behaviors, including cancer cell invasion [21], proliferation, drug resistance [22,23], cancer stem cell maintenance [24], and immunosurveillance evasion [22,25,26].”
BackgroundEnhanced EPR effects by tumour stromal cell mimicking nanoplatform on invasive pituitary adenoma
Ma, J., Wei, Y., Zhang, X., Lu, L., Bao, Y., Dai, L., Cao, H., Chen, H.-C., Yu, J., Yang, J., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100895 · Cited by 27
“Unfortunately, most attempts at manipulating the tumour microenvironment failed during Phase III trials due to low efficacy [4,5].”
BackgroundCancer drug sensitivity prediction from routine histology images
Dawood, M., Vu, Q. D., Young, L. S., Branson, K., Jones, J. L., Rajpoot, N., & Minhas, F. (2024) · npj Precision Oncology · doi:10.1038/s41698-023-00491-9 · Cited by 26
“We analysed both tumour and non-tumour patches based on the hypothesis that patients sensitivity to compounds can be in fl uenced by interactions among different cell types (including stromal cells) in the TME 54 – 56 .”
MethodAbcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response
Domanitskaya, N., Wangari‐Talbot, J., Jacobs, J. D., Peiffer, E., Mahdaviyeh, Y., Paulose, C., Malofeeva, E. V., Foster, K., Cai, K. Q., Zhou, Y., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.326 · Cited by 23
“Such unexpected activities might also affect drug resistance, by affecting the proliferation rate of tumours, or by contributing to epithelial–mesenchymal transitions that are associated with general drug resistance (Dave et al, 2012; McMillin et al, 2013).”
BackgroundBreast tumors educate the proteome of stromal tissue in an individualized but coordinated manner
Wang, X., Mooradian, A. D., Erdmann-Gilmore, P., Zhang, Q., Viner, R., Davies, S. R., Huang, K., Bomgarden, R. D., Tine, B. A. V., Shao, J., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aam8065 · Cited by 25
Zhou, Q. S., Guo, X., & Choksi, R. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240507 · Cited by 24
“…using an A549 human lung adenocarcinoma xenograft model, we were able to explore the mechanisms of acquired sorafenib resistance in the context of tumor microenvironment, which is known to contribute substantially to the acquisition of tumor resistance to targeted therapies (McMillin et al., 2013).”
BackgroundRăileanu, M., POPESCU, A. I., & Bacalum, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186964 · Cited by 24
“Some of the obstacles are due to intratumor complexity and heterogeneity and to cell interactions inside the tumor or with the surrounding microenvironment [1,2].”
BackgroundMesenchymal Stem Cells Engineered by Nonviral Vectors: A Powerful Tool in Cancer Gene Therapy
Ding, Y., Wang, C., Sun, Z., Wu, Y., You, W., Mao, Z., & Wang, W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060913 · Cited by 24
Koch, H., Wilhelm, M., Ruprecht, B., Beck, S., Frejno, M., Klaeger, S., & Küster, B. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00621 · Cited by 24
Dou, Y. N., Chaudary, N., Chang, M. C., Dunne, M., Huang, H., Jaffray, D. A., Milosevic, M., & Allen, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.039 · Cited by 21
3D stem-like spheroids-on-a-chip for personalized combinatorial drug testing in oral cancer
Mehta, V., Sudhakaran, S. V., Nellore, V., Madduri, S., & Rath, S. N. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02625-y · Cited by 23
“Moreover, the stromal cells significantly affect the drug response [73].”
BackgroundRousset, X., Maillet, D., Grolleau, E., Barthélémy, D., Calattini, S., Brevet, M., Balandier, J., Raffin, M., Geiguer, F., Garcia, J., et al. (2022) · Cancers · doi:10.3390/cancers14174085 · Cited by 21
Gevertz, J. L., Aminzare, Z., Norton, K., Pérez-Velázquez, J., Volkening, A., & Rejniak, K. A. (2015) · The IMA volumes in mathematics and its applications · doi:10.1007/978-1-4939-2782-1_1 · Cited by 23
Resistance to targeted cancer drugs through hepatocyte growth factor signaling
Heynen, G. J. J. E., Fonfara, A., & Bernards, R. (2014) · Cell Cycle · doi:10.4161/15384101.2014.988033 · Cited by 23
“This can potentially affect the response of tumor cells to drugs.(40) For instance, stromal cells can produce growth factors and cytokines that could be exploited in a paracrine fashion by the tumor cells.”
BackgroundDrug Discovery Testing Compounds in Patient Samples by Automated Flow Cytometry
Hernández, P., Gorrochategui, J., Primo, D., Robles, A., Rojas, J. L., Espinosa, A. B., Gómez, C., Martínez‐López, J., Bennett, T. A., & Ballesteros, J. (2017) · SLAS TECHNOLOGY · doi:10.1177/2472630317700346 · Cited by 21
“It is well known that the tumor microenvironment (TME) affects tumor cell survival, proliferation, and drug resistance.(7,8) Its role has become even more important with the discovery and development of cancer drugs that specifically target its components.”
BackgroundFlont, M., Jastrzębska, E., & Brzózka, Z. (2020) · The Analyst · doi:10.1039/d0an00911c · Cited by 21
Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold
Hu, L., Yang, X. F., Lan, H., Fang, X., Chen, X., & Jin, K. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112858 · Cited by 22
Pătraș, L., & Banciu, M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190701143845 · Cited by 21
3D Bioprinting for Engineering Organoids and Organ‐on‐a‐Chip: Developments and Applications
Ren, Y., Yuan, C., Liang, Q., Ba, Y., Xu, H., Weng, S., Zhang, Y., Zuo, A., Liu, S., Luo, P., et al. (2025) · Medicinal Research Reviews · doi:10.1002/med.22121 · Cited by 23
Implementing precision medicine initiatives in the clinic: a new paradigm in drug development
Hollebecque, A., Massard, C., & Soria, J. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000077 · Cited by 20
Shi, C.-J., Xue, Z.-H., Zeng, W.-Q., Deng, L.-Q., Pang, F., Zhang, F., Fu, W.-M., & Zhang, J. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00595-1 · Cited by 21
Zhao, Y., Weng, Z., Zhou, X., Xu, Z., Cao, B., Wang, B., & Li, J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04063-0 · Cited by 23
“Upon integration into the TME and subsequent interaction with tumor cells, MSC are known to exert influence on multiple cancer hallmarks, such as the development of chemotherapy resistance [12, 13].”
BackgroundBreast cancer organoids and their applications for precision cancer immunotherapy
Guan, D., Liu, X., Shi, Q., He, B., Zheng, C., & Meng, X. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03231-2 · Cited by 23
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1462293 · Cited by 22
Al-Thawadi, H., Abu-Kaoud, N., Farsi, H. A., Hoarau-Véchot, J., Rafii, S., Rafii, A., & Pasquier, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6677 · Cited by 21
“Clinical and experimental evidences indicate that tumor initiation and progression is intimately related to the complex dialogue between tumor microenvironment and malignant cells [1, 2].”
BackgroundShielding and nurturing: Fibronectin as a modulator of cancer drug resistance
Farooq, F., Amin, A., Wani, U. M., Lone, A., & Qadri, R. A. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31048 · Cited by 21
Macedo, R., Rochefort, J., Guillot‐Delost, M., Tanaka, K., Moignic, A. L., Noizat, C., Baillou, C., Mateo, V., Carpentier, A. F., Tartour, É., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1164363 · Cited by 19
Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment
Dhimolea, E., Simoes, R. D. M., Kansara, D. N., Weng, X., Sharma, S., Awate, P., Liu, Z., Gao, D., Mitsiades, N., Schwab, J. H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0571 · Cited by 21
“We reasoned that it is biologically plausible for BMSCs to play such a role in the bonemilieu, amain site formetastases of HRþ breast cancer and prostate cancer, because extensive studies in hematologic neoplasias have documented that BMSCs can confer to them cell nonautonomous resistance against diverse pharmacologic…”
BackgroundSelf-citationCollins, A., Miles, G. J., Powley, I. R., Hew, R., Pringle, J. H., MacFarlane, M., Pritchard, C. A., & Moss, E. L. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.11.033 · Cited by 20
Leong, T. K. M., Lo, W. S., Lee, W. E. Z., Tan, B., Lee, X. Z., Lee, L. W. J. N., Lee, J.-Y. J., Suresh, N., Loo, L., Szu, E., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113959 · Cited by 20
Krulikas, L. J., McDonald, I. M., Lee, B., Okumu, D. O., East, M. P., Gilbert, T. S. K., Herring, L. E., Golitz, B. T., Wells, C. I., Axtman, A. D., et al. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218773045 · Cited by 21
Flickinger, K. M., Wilson, K. M., Rossiter, N. J., Hunger, A. L., Vishwasrao, P., Lee, T. D., Fritz, C. M., Richards, R. M., Hall, M. D., & Cantor, J. R. (2024) · Science Advances · doi:10.1126/sciadv.adq3591 · Cited by 19
Exploring Drug Dosing Regimens In Vitro Using Real-Time 3D Spheroid Tumor Growth Assays
Lal‐Nag, M., McGee, L. E., Titus, S. A., Brimacombe, K. R., Michael, S., Sittampalam, G. S., & Ferrer, M. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217698818 · Cited by 20
Abdellateif, M. S., Salem, S., Badr, D. M., Shaarawy, S., Hussein, M. M., Zekri, A. N., & Fouad, M. A. (2020) · Journal of Inflammation Research · doi:10.2147/jir.s283069 · Cited by 18
Overview of DNA repair pathways, current targets, and clinical trials bench to clinic
Kelley, M. R., & Fishel, M. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00001-2 · Cited by 21
Bergamo, A., Pelillo, C., Chambery, A., & Sava, G. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.11.031 · Cited by 19
Doron, B., Handu, M., & Kurre, P. (2017) · Stem Cells · doi:10.1002/stem.2761 · Cited by 17
Chen, J., Ren, Q., Cai, Y., Lin, T., Zuo, W., Wang, J., Lin, R., Zhu, L., Wang, P., Dong, H., et al. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.218 · Cited by 17
Organoids Are Limited in Modeling the Colon Adenoma–Carcinoma Sequence
Tokumaru, Y., Oshi, M., Patel, A. P., Tian, W., Yan, L., Matsuhashi, N., Futamura, M., Yoshida, K., & Takabe, K. (2021) · Cells · doi:10.3390/cells10030488 · Cited by 17
“The lack of an appropriate system to model human cancer is the reasons many phase III clinical trials fail [8].”
BackgroundFogli, S., Galimberti, S., Gori, V., Re, M. D., & Danesi, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105537 · Cited by 17
Chen, Y., Zhang, X., Lu, X., Wu, H., Zhang, D., Zhu, B., & Huang, S. (2021) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2021.120634 · Cited by 17
Endothelial cell–leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities
Cappelli, L. V., Fiore, D., Phillip, J. M., Yoffe, L., Giacomo, F. D., Chiu, W., Hu, Y., Kayembe, C., Ginsberg, M. D., Consolino, L., et al. (2022) · Blood · doi:10.1182/blood.2022015414 · Cited by 17
Zhu, M., Li, X., Xu, C. W., Ye, F., Ye, F., Li, X., Hu, Z., Zhang, L., Nie, J. J., & Li, X. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01252-6 · Cited by 19
López‐Millán, B., de la Guardia, R. D., Roca-Ho, H., Anguita, E., Islam, A. B. M. M. K., Romero–Moya, D., Prieto, C., Gutiérrez‐Agüera, F., Bejarano-García, J. A., Pérez‐Simón, J. A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1477460 · Cited by 16
Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives
Loda, A., Turati, M., Semeraro, F., Rezzola, S., & Ronca, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073835 · Cited by 16
“Besides their pro-tumor activity exerted on cancer cells, tumor-derived FGFs also mediate tumor/stroma crosstalk, thus playing a relevant role in conditioning the surrounding stromal cells and favoring the onset of a pro-tumor microenvironment [53,54].”
BackgroundNanonets Collect Cancer Secretome from Pericellular Space
Zhou, R., Kuang, Y., Zhou, J., Du, X., Li, J., Shi, J., Haburcak, R., & Xu, B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154126 · Cited by 16
“[2] However, the definitive identification of cancer biomarkers remains a major challenge because the proteins in cancer secretome, the key soluble constituents of tumor microenvironments, [3,4] are dynamic and complex.”
BackgroundDhar, D., Raina, K., Kant, R., Wempe, M. F., Serkova, N. J., Agarwal, C., & Agarwal, R. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz114 · Cited by 18
“Due to the severity of PanC and its related complex metabolic profile, a variety of targeted therapies/therapeutic agents have proven unsuccessful or deemed ineffective in the clinic (16).”
BackgroundLi, N. Y., Zhang, W., Haensel, D., Jussila, A. R., Pan, C., Gaddam, S., Plevritis, S. K., & Oro, A. E. (2024) · Nature Communications · doi:10.1038/s41467-024-52394-3 · Cited by 16
“A blank cycle containing no fl uorescent probes was performed at the beginning, middle and end of the imaging cycles to capture auto fl uorescence (Supplementary Data 2).”
InfluentialArumuggam, N., Melong, N., Too, C. K. L., Berman, J. N., & Rupasinghe, H. P. V. (2017) · PubMed · Cited by 21
Hußtegge, M., Hoang, N. A., Rebstock, J., Monecke, A., Gockel, I., Weimann, A., Schumacher, G., Bechmann, I., Lordick, F., Kallendrusch, S., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1960729 · Cited by 17
Sun, Y., Yang, N., Utama, F. E., Udhane, S. S., Zhang, J., Peck, A. R., Yanac, A. F., Duffey, K. E., Langenheim, J. F., Udhane, V., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc8145 · Cited by 15
“…progress is being made with patient-derived tumor organoids cultured in plastic for personalized cancer medicine ( 57 – 59 ), the known modulatory effects of tumor microenvironment factors on therapeutic responses of cancer ( 60 , 61 ) remain a limitation of stroma-free tumor organoid cultures.”
Hakuno, S. K., Michiels, E., Kuhlemaijer, E. B., Rooman, I., Hawinkels, L. J. A. C., & Slingerland, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063147 · Cited by 15
“Not all cancer cell subclones are reflected accurately in a (clonal) cell line and, importantly, there is a lack of the TME, resulting in no 3D cell–cell interactions and/or tumour–stroma interactions [31,32].”
BackgroundFranzini, A., Baty, F., Macovei, I. I., Dürr, O., Droege, C., Betticher, D. C., Grigoriu, B. D., Klingbiel, D., Zappa, F., & Brutsche, M. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3135 · Cited by 15
“These tumor-associated stromal components have been demonstrated to have an important role in tumor growth, disease progression (3) as well as in response and resistance to therapeutic agents (4, 5).”
BackgroundJinushi, M., Yagita∥, H., Yoshiyama, H., & Tahara, H. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.06.001 · Cited by 16
Ren, L., & Konger, R. L. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23041 · Cited by 15
“microenvironment into one more hospitable for tumor development and less prone to antitumor immune reactions.(79,80)”
Functional biomaterials for biomimetic 3D in vitro tumor microenvironment modeling
Ahmed, T. (2023) · In vitro models · doi:10.1007/s44164-023-00043-2 · Cited by 14
Challenges in the preclinical design and assessment of CAR-T cells
Tomai, R. A., Rivas, J. D. L., Fetică, B., Bergantim, R., Filipić, B., Gagić, Ž., Nikolic, K. M., Gulei, D., Kegyes, D., Nistor, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1564998 · Cited by 15
“This discrepancy can be attributed to the exclusion of the in fl uence of the tumor microenvironment (TME) on tumor survival, progression, and resistance development in in vivo immunode fi cient models as it happens in immune-de fi cient mouse models (75).”
Multitarget Inhibitors Derived from Crosstalk Mechanism Involving VEGFR2
Ding, C., Zhang, C., Zhang, M., Chen, Y., Tan, C., Tan, Y., & Jiang, Y. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.112 · Cited by 14
Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs
Ahmed, T., Liu, F.-C. F., Lu, B., Lip, H., Park, E., Alradwan, I. A., Liu, J. F., He, C., Zetrini, A., Zhang, T., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00038 · Cited by 15
Lewin, J. H., & Siu, L. L. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000185 · Cited by 14
In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles
Abreu, T. R., Biscaia-Caleiras, M., Gonçalves, N., Fonseca, N. A., & Moreira, J. N. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_12 · Cited by 18
Metadata
- Authors
- McMillin, D. W., Negri, J. M., & Mitsiades, C. S.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Corresponding author
- Mitsiades, Constantine S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-03
- Volume
- 12
- Issue
- 3
- Pages
- 217-228
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1980669422
- Cited by
- 474
- References
- 150
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 27 · 2023: 34 · 2022: 29 · 2021: 43 · 2020: 41 · 2019: 33 · 2018: 49 · 2017: 56 · 2016: 41 · 2015: 40 · 2014: 27 · 2013: 16
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (R0-1 50947)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Keywords
- tumor microenvironment, stromal cells, drug resistance, drug sensitivity, anticancer drug discovery, preclinical models, orthotopic xenograft, metastasis
- MeSH terms
- Animals, Antineoplastic Agents, Drug Evaluation, Preclinical, Drug Screening Assays, Antitumor, Humans, Neoplasms, Stromal Cells, Drug Resistance, Neoplasm, Drug Discovery, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.